ISRCTN27362692已完成不适用
Intranasal zolmitriptan is effective and well tolerated in acute cluster headache
AstraZeneca (UK)0 个研究点目标入组 90 人开始时间: 2006年2月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Cluster headache with attacks longer than 45 minutes.
排除标准
- •Contraindications to zolmitriptan in participating countries.
研究者
相似试验
已完成
3 期
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in AdolescentsMigraineNCT00617695Impax Laboratories, LLC247
Unknown
4 期
Efficacy and Safety of Zolmitriptan by Sublingual AdministrationCluster HeadacheNCT03377257Xijing Hospital71
已完成
3 期
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLEMigraineNCT03275922Impax Laboratories, LLC374
进行中（未招募）
不适用
Efficacy of intranasal administration of haloperidol compared to intramuscular administration in agitated schizophrenic patientsEUCTR2014-001157-17-ESFundació Parc Taulí40
终止
3 期
Midazolam Nasal Spray for the treatment of breathlessness in patients with life-limiting diseaseDyspnoea (Breathlessness)Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12609000506291Arohanui Hospice Service Trust, Clare Randall as representative200